MMVF Twitter
Financing Solutions that Fit
MONTREAL -- Galileo's proprietary platform is designed for the identification of genes associated with common and economically important diseases and the rapid production of high quality targets for drug development and diagnostic products. By identifying genes and understanding their biological function, the Company hopes to discover the causes of many physical disorders that can arise with genetic variations. Galileo's research relies on the study of genetic data collected from the Quebec founder population and the Company is using its proprietary technologies to build the one of the world's leading DNA databanks.

"The quality of Galileo's team and the compelling value proposition of their technology have positioned them to become a leading population genomics company." said Ron Patterson, Partner of MM Venture Partners. "We have a great deal of confidence in Galileo's core process and strongly believe it will be a significant player in the fast growing fields of population genetics and disease gene discovery."

"This financing strengthens our cash position and provides more working capital for Galileo to continue to develop its business," said Dr. John Hooper, President and CEO of Galileo. "We are very pleased to have MM Venture Partners on board. Their technical and financial expertise and strong market credibility provides further validation for Galileo."

About Galileo Genomics Inc.
Galileo Genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for the creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest such population worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations. For further information please visit

About MM Venture Partners
MM Venture Partners is a privately held, venture-debt fund that focuses exclusively on private technology companies in Canada, specifically Canadian information technology and biotechnology companies. For further information please visit

For more information, please contact:

Galileo Genomics Inc.
Mariano Rodriguez
Vice President and Chief Financial Officer
Tel: (514) 270-3991 ext. 230

MM Venture Partners
Ron Patterson
Tel: 416-977-9718

Posted in: Life Sciences

MMV :: 370 King Street West, Suite 442 Toronto ON M5V 1J9 Canada